Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jun;40(6):1335–1337. doi: 10.1128/aac.40.6.1335

Rifapentine is active in vitro and in vivo against Toxoplasma gondii.

F G Araujo 1, A A Khan 1, J S Remington 1
PMCID: PMC163326  PMID: 8725996

Abstract

Rifapentine, a derivative of rifamycin, was examined for its in vitro and in vivo activities against the protozoan parasite Toxoplasma gondii. The drug inhibited the intracellular replication of parasites and was not cytotoxic for the host cells at inhibitory concentrations. Mice infected either intraperitoneally with tachyzoites of the RH strain or orally with tissue cysts of the C56 strain were protected against death by treatment with rifapentine. The degree of protection was similar to that induced by atovaquone and apparently higher than that induced by rifabutin. Rifapentine may be a useful drug for the treatment of toxoplasmosis in immunocompromised individuals.

Full Text

The Full Text of this article is available as a PDF (222.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araujo F. G., Huskinson J., Remington J. S. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother. 1991 Feb;35(2):293–299. doi: 10.1128/aac.35.2.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Araujo F. G., Slifer T., Remington J. S. Rifabutin is active in murine models of toxoplasmosis. Antimicrob Agents Chemother. 1994 Mar;38(3):570–575. doi: 10.1128/aac.38.3.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Assandri A., Ratti B., Cristina T. Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. J Antibiot (Tokyo) 1984 Sep;37(9):1066–1075. doi: 10.7164/antibiotics.37.1066. [DOI] [PubMed] [Google Scholar]
  4. Brown S. T., Edwards F. F., Bernard E. M., Tong W., Armstrong D. Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine. Antimicrob Agents Chemother. 1993 Mar;37(3):398–402. doi: 10.1128/aac.37.3.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chapuis L., Ji B., Truffot-Pernot C., O'Brien R. J., Raviglione M. C., Grosset J. H. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1355–1362. doi: 10.1164/ajrccm.150.5.7952564. [DOI] [PubMed] [Google Scholar]
  6. Israelski D. M., Remington J. S. Toxoplasmic encephalitis in patients with AIDS. Infect Dis Clin North Am. 1988 Jun;2(2):429–445. [PubMed] [Google Scholar]
  7. Klemens S. P., Cynamon M. H. Activity of rifapentine against Mycobacterium avium infection in beige mice. J Antimicrob Chemother. 1992 May;29(5):555–561. doi: 10.1093/jac/29.5.555. [DOI] [PubMed] [Google Scholar]
  8. Klemens S. P., Grossi M. A., Cynamon M. H. Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex. Antimicrob Agents Chemother. 1994 Feb;38(2):234–237. doi: 10.1128/aac.38.2.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Laughon B. E., Allaudeen H. S., Becker J. M., Current W. L., Feinberg J., Frenkel J. K., Hafner R., Hughes W. T., Laughlin C. A., Meyers J. D. From the National Institutes of Health. Summary of the workshop on future directions in discovery and development of therapeutic agents for opportunistic infections associated with AIDS. J Infect Dis. 1991 Aug;164(2):244–251. doi: 10.1093/infdis/164.2.244. [DOI] [PubMed] [Google Scholar]
  10. Luft B. J., Hafner R., Korzun A. H., Leport C., Antoniskis D., Bosler E. M., Bourland D. D., 3rd, Uttamchandani R., Fuhrer J., Jacobson J. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med. 1993 Sep 30;329(14):995–1000. doi: 10.1056/NEJM199309303291403. [DOI] [PubMed] [Google Scholar]
  11. Mitchison D. A., Ellard G. A., Grosset J. New antibacterial drugs for the treatment of mycobacterial disease in man. Br Med Bull. 1988 Jul;44(3):757–774. doi: 10.1093/oxfordjournals.bmb.a072281. [DOI] [PubMed] [Google Scholar]
  12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES